The Most Important Pharmacovigilance Terms and Definitions Explained in Practical Language
Key Takeaways
- Understanding pharmacovigilance terminology is essential for compliance, inspections, and effective communication.
- Many inspection findings originate from inconsistent interpretation of regulatory definitions.
- Pharmacovigilance professionals should understand not only definitions but also their practical application.
- Global regulations use common terminology, but interpretation often requires operational understanding.
- A strong vocabulary supports better decision-making across all pharmacovigilance activities.
Pharmacovigilance is a terminology-heavy discipline. Every day, professionals use hundreds of abbreviations, regulatory concepts, technical terms, and safety definitions while processing cases, conducting signal reviews, preparing aggregate reports, participating in inspections, and managing compliance activities.
For newcomers, the language of pharmacovigilance can feel overwhelming.
For experienced professionals, precise terminology remains equally important because regulators, auditors, inspectors, vendors, and internal stakeholders rely on common definitions to communicate effectively.
Misunderstanding a single term can lead to incorrect reporting decisions, weak investigations, compliance risks, or inspection findings.
This reference article explains many of the most important pharmacovigilance terms in practical language, focusing not only on definitions but also on how they are applied in real-world drug safety operations.
1. Fundamental Pharmacovigilance Definitions
Pharmacovigilance (PV)
The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problems.
Drug Safety
A commonly used operational term referring to activities performed within pharmacovigilance systems to monitor and manage medicine-related risks.
Benefit-Risk Balance
The overall evaluation of a medicine’s therapeutic benefits compared with its known and potential risks.
Safety Signal
Information suggesting a new potentially causal association or a new aspect of a known association between a product and an event.
Signals require evaluation before conclusions are reached.
2. Adverse Event Reporting Terminology
Adverse Event (AE)
Any untoward medical occurrence in a patient who has received a medicinal product, regardless of whether a causal relationship exists.
Adverse Reaction (AR)
An adverse event where a causal relationship with the medicinal product is at least reasonably possible.
Serious Adverse Event (SAE)
An adverse event that results in outcomes such as:
- Death
- Life-threatening situations
- Hospitalization
- Persistent disability
- Congenital anomalies
Unexpected Adverse Reaction
An adverse reaction whose nature, severity, or outcome is not consistent with available product information.
3. Individual Case Safety Report Terminology
ICSR
Individual Case Safety Report. A structured report containing information about a patient experiencing an adverse event or reaction.
Valid Case
A report meeting minimum reporting criteria:
- Identifiable patient
- Identifiable reporter
- Suspect product
- Adverse event
Follow-Up Information
Additional information received after initial case creation that helps clarify or complete safety assessments.
Duplicate Case
Multiple reports describing the same patient and event.
Duplicate detection remains an important pharmacovigilance quality activity.
4. Clinical Trial Safety Terminology
SUSAR
Suspected Unexpected Serious Adverse Reaction.
A serious reaction that is suspected to be related to the investigational product and is unexpected based on current safety information.
DSUR
Development Safety Update Report.
An annual report summarizing the safety profile of an investigational product during development.
Investigator Brochure (IB)
A document containing clinical and nonclinical information about an investigational product.
SAE Reconciliation
The process of comparing safety databases with clinical trial databases to ensure completeness and consistency.
5. Signal Detection and Risk Management Terminology
Signal Detection
The process of identifying potential safety concerns from available safety data.
Signal Validation
The initial evaluation determining whether a potential signal warrants further investigation.
Signal Assessment
Detailed scientific evaluation of validated signals.
Risk Management Plan (RMP)
A document describing known risks, potential risks, and activities used to monitor and minimize those risks.
Risk Minimization Measure
Actions implemented to reduce the likelihood or severity of identified risks.
6. Aggregate Reporting Terminology
PSUR
Periodic Safety Update Report.
A report summarizing cumulative safety information for a marketed product.
PBRER
Periodic Benefit-Risk Evaluation Report.
An enhanced version of periodic reporting emphasizing benefit-risk evaluation.
Line Listing
A tabulated summary of individual cases used for analysis and reporting.
Cumulative Analysis
Evaluation of safety information collected over the entire lifecycle of a product.
7. Governance and Oversight Terminology
QPPV
Qualified Person Responsible for Pharmacovigilance.
The individual responsible for oversight of the pharmacovigilance system.
PSMF
Pharmacovigilance System Master File.
A document describing the pharmacovigilance system and how it operates.
Governance Committee
A group responsible for reviewing safety information, compliance metrics, and emerging risks.
Escalation
The process of communicating significant risks or issues to appropriate decision-makers.
8. Quality and Compliance Terminology
Deviation
A departure from approved procedures, requirements, or expected processes.
CAPA
Corrective and Preventive Action.
A structured process used to investigate issues, address root causes, and prevent recurrence.
Root Cause Analysis
A systematic investigation designed to identify the underlying causes of a problem.
Effectiveness Check
An activity performed to verify that corrective actions successfully resolved the identified issue.
9. MedDRA and Coding Terminology
MedDRA
Medical Dictionary for Regulatory Activities.
The global medical terminology used for coding pharmacovigilance information.
LLT
Lowest Level Term.
The most detailed level within the MedDRA hierarchy.
PT
Preferred Term.
The primary level used for analysis and reporting.
SOC
System Organ Class.
The highest level within the MedDRA hierarchy.
10. Inspection and Audit Terminology
Inspection
A regulatory authority assessment evaluating compliance with applicable requirements.
Audit
An independent evaluation of processes, systems, and compliance activities.
Critical Finding
An observation indicating significant risk to patient safety or substantial regulatory noncompliance.
Major Finding
An observation indicating significant weaknesses that require corrective action.
Minor Finding
An observation involving limited impact but requiring improvement.
Understanding these terms helps professionals communicate effectively during audits and inspections.
Related Resources
FAQs
Why is pharmacovigilance terminology important?
Consistent terminology supports accurate communication, regulatory compliance, inspections, and operational decision-making.
What is the difference between an adverse event and an adverse reaction?
An adverse event does not require a causal relationship, while an adverse reaction involves at least a reasonable possibility of causality.
What is a valid case?
A report containing an identifiable patient, identifiable reporter, suspect product, and adverse event.
What is the difference between PSUR and DSUR?
PSURs generally relate to marketed products, while DSURs focus on investigational products in clinical development.
Why do inspectors review definitions and terminology?
Because inconsistent interpretation often leads to reporting errors, compliance failures, and poor decision-making.
Key Reference Notes
- Review pharmacovigilance terminology regularly during training programs.
- Use consistent definitions across SOPs, training materials, and governance activities.
- Verify that vendors apply terminology consistently.
- Include terminology reviews during inspection readiness exercises.
- Update training content when major regulatory definitions evolve.
Regulatory and Authoritative References
- EMA Good Pharmacovigilance Practices (GVP)
- ICH Pharmacovigilance and Efficacy Guidelines
- WHO Uppsala Monitoring Centre